Sernova Biotherapeutics Inc
SVA.TO
TSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.57% | -17.82% | -10.27% | -24.60% | -8.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.66% | -51.24% | -57.84% | -54.52% | -60.57% |
| Operating Income | 49.66% | 51.24% | 57.84% | 54.52% | 60.57% |
| Income Before Tax | 55.33% | 46.41% | 64.09% | 44.53% | 57.84% |
| Income Tax Expenses | -876.47% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.48% | 46.13% | 63.73% | 44.47% | 57.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.48% | 46.13% | 63.73% | 44.47% | 57.78% |
| EBIT | 49.66% | 51.24% | 57.84% | 54.52% | 60.57% |
| EBITDA | 50.42% | 51.60% | 57.87% | 54.50% | 60.65% |
| EPS Basic | 58.26% | 50.28% | 66.53% | 48.74% | 59.51% |
| Normalized Basic EPS | 56.94% | 49.56% | 66.89% | 48.99% | 59.55% |
| EPS Diluted | 58.26% | 50.28% | 66.53% | 48.74% | 59.51% |
| Normalized Diluted EPS | 56.94% | 49.56% | 66.89% | 48.99% | 59.55% |
| Average Basic Shares Outstanding | 3.54% | 8.20% | 8.27% | 7.96% | 4.67% |
| Average Diluted Shares Outstanding | 3.54% | 8.20% | 8.27% | 7.96% | 4.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |